Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0H9BP
|
||||
| Former ID |
DIB021228
|
||||
| Drug Name |
xanthine amine congener
|
||||
| Synonyms |
papaxac
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C21H28N6O4
|
||||
| InChI |
InChI=1S/C21H28N6O4/c1-3-11-26-19-17(20(29)27(12-4-2)21(26)30)24-18(25-19)14-5-7-15(8-6-14)31-13-16(28)23-10-9-22/h5-8H,3-4,9-13,22H2,1-2H3,(H,23,28)(H,24,25)
|
||||
| InChIKey |
FIQGIOAELHTLHM-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
5455855, 7980895, 8153492, 11111969, 14832106, 17405833, 24277745, 29224734, 47217013, 47359839, 47440501, 47805486, 47811001, 50107234, 50107235, 52225234, 53778385, 57322898, 85090417, 85209664, 85231286, 90340726, 92303217, 103579012, 103831832, 104309992, 117540046, 124750378, 124881826, 125165329, 127852773, 134224386, 135080024, 135651217, 135651329, 137014787, 138080078, 139569057, 162091057, 163138682, 163565233, 179151484, 227255507, 245019684, 250129973
|
||||
| Target and Pathway | |||||
| Target(s) | Adenosine A3 receptor | Target Info | Antagonist | [2] | |
| Adenosine A2b receptor | Target Info | Antagonist | [3] | ||
| Adenosine A1 receptor | Target Info | Antagonist | [4] | ||
| KEGG Pathway | Rap1 signaling pathway | ||||
| Calcium signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Vascular smooth muscle contraction | |||||
| Alcoholismhsa04022:cGMP-PKG signaling pathway | |||||
| cAMP signaling pathway | |||||
| Sphingolipid signaling pathway | |||||
| Morphine addiction | |||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| TCR Signaling PathwayNetPath_11:TCR Signaling Pathway | |||||
| RANKL Signaling Pathway | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Pathway Interaction Database | C-MYB transcription factor network | ||||
| PathWhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2b and Adenosine | ||||
| Reactome | Adenosine P1 receptors | ||||
| G alpha (i) signalling eventsR-HSA-417973:Adenosine P1 receptors | |||||
| G alpha (s) signalling events | |||||
| Surfactant metabolismR-HSA-417973:Adenosine P1 receptors | |||||
| G alpha (i) signalling events | |||||
| WikiPathways | Nucleotide GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCRs, OtherWP80:Nucleotide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP80:Nucleotide GPCRs | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 404). | ||||
| REF 2 | [(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors. Mol Pharmacol. 2000 May;57(5):968-75. | ||||
| REF 3 | Use of the triazolotriazine [3H]ZM 241385 as a radioligand at recombinant human A2B adenosine receptors. Drug Des Discov. 1999 Nov;16(3):217-26. | ||||
| REF 4 | Species difference in the G protein selectivity of the human and bovine A1-adenosine receptor. J Biol Chem. 1994 Dec 23;269(51):32077-84. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.